Last reviewed · How we verify
NCT01399437
Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia
trial in Schizophrenia in 64 participants. Completed in 24 December 2014.
Quick facts
| Lead sponsor | National Institute on Drug Abuse (NIDA) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 3 July 2011 |
| Estimated completion | 24 December 2014 |
| Sites | 1 location across United States |
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
National Institute on Drug Abuse (NIDA)
Who can join
Adults 18 to 55, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: \- A special brain circuit is important for helping us keeping an eye open for things that are going on around us, even when we are not directly paying attention to them. This circuit seems to work differently in people with schizophrenia than in other people, which may explain specific deficits with broad monitoring observed in people with schizophrenia. Researchers want to compare brain function in people with schizophrenia and healthy volunteers to find out more about how these brain circuits work and affect attention. Objectives: \- To study how the brain performs broad visual monitoring in people with schizophrenia. Eligibility: * Individuals between 18 to 55 years of age who have been diagnosed with schizophrenia. * Healthy volunteers between 18 and 55. Design: * Participants will be screened with physical and psychological exams. They will have a medical history. Tests for drug and alcohol use will also be done. * Participants will have two study visits. The first is a training visit and the second is a scanning visit. * At the training visit, participants will practice computer-based tests of focus, memory, and concentration. They will also answer questions about mood, psychiatric symptoms, and smoking habits. * At the scanning visit, participants will perform the computer-based tasks that they practiced at the training visit. They will have magnetic resonance imaging while they perform these tasks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01399437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other National Institute on Drug Abuse (NIDA) trials
Trials by the same sponsor.
- NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
- NCT06808932 — VK4-116 Phase I Study With Food-Effect · Phase 1 · not yet recruiting
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06577454 — Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Sub · NA · suspended
- NCT06868914 — Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01399437 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA)
- Last refreshed: 5 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01399437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing